Acrodermatitis continua of Hallopeau (ACH) is a rare type of pustular psoriasis affecting the digits. We report on a 43-year-old female patient who had been suffering from ACH for more than 20 years. Despite the fact that the disease was localized on one finger during the whole period, several topical and systemic treatments resulted in only temporary or partial improvement of the lesion. Although the monotherapies with calcipotriol and tacrolimus ointments gave no satisfying results in the long-term management of the disease, the combination of both agents led to a continuous improvement of the patient’s skin condition.

Keywords:
Acrodermatitis continua of Hallopeau, Pustular psoriasis, Calcipotriol, Tacrolimus
1.
Hallopeau MH: Sur une asphyxie locale des extrémités avec polydactylite suppurative chronique et poussées éphémères de dermatite pustuleuse disséminée et symétrique. Soc Fr Dermatol Syph Bull 1890;1:39–45.
2.
Christophers E, Mrowietz U: Pustular eruptions of palms and soles; in Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (eds): Fitzpatrick’s Dermatology in General Medicine, ed 6. New York, McGraw-Hill, 2003, pp 628–632.
3.
Piquero-Casals J, Fonseca de Mello AP, Dal Coleto C, Fonseca Takahashi MD, Simonsen Nico MM: Using oral tetracycline and topical betamethasone valerate to treat acrodermatitis continua of Hallopeau. Cutis 2002;70:106–108.
4.
Nikkels AF, Nikkels-Tassoudji N, Piérard GE: Breaking the relentless course of Hallopeau’s acrodermatitis by dapsone. Eur J Dermatol 1999;9:126–128.
5.
Emtestam L, Weden U: Successful treatment for acrodermatitis continua of Hallopeau using topical calcipotriol. Br J Dermatol 1996;135:644–646.
6.
Tsuji T, Nishimura M: Topically administered fluorouracil in acrodermatitis continua of Hallopeau. Arch Dermatol 1991;127:27–28.
7.
Kokelj F, Plozzer C, Trevisan G: Uselessness of topical calcipotriol as monotherapy for acrodermatitis continua of Hallopeau. Acta Derm Venereol 2001;81:153.
8.
Wilsmann-Theis D, Hagemann T, Dederer H, Wenzel J, Bieber T, Novak N: Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. Br J Dermatol 2004;150:1194–1197.
9.
Bauer W, Calkins E, Reznick L: Clinical and metabolic effects of prednisone, prednisolone and cortisone in a patient with acrodermatitis continua (Hallopeau). N Engl J Med 1957;256:245–250.
10.
Kuijpers AL, van Dooren-Greebe RJ, van de Kerkhof PC: Acrodermatitis continua of Hallopeau: Response to combined treatment with acitretin and calcipotriol ointment. Dermatology 1996;192:357–359.
11.
Behrens S, von Kobyletzki G, Hoffmann K, Altmeyer P, Kerscher M: PUVA-Bad-Photochemotherapie bei Acrodermatitis continua suppurativa Hallopeau. Hautarzt 1997;48:824–827.
12.
Chowdhury MM, Motley RJ: Treatment of acrodermatitis continua of Hallopeau with oral propylthiouracil and methotrexate. Clin Exp Dermatol 2001;26:657–660.
13.
Korstanje MJ, Bessems PJ, Hulsmans RF, van de Staak WJ: Pustular psoriasis and acrodermatitis continua (Hallopeau) need high doses of systemic ciclosporin A. Dermatologica 1989;179:90–91.
14.
Mang R, Ruzicka T, Stege H: Successful treatment of acrodermatitis continua of Hallopeau by the tumour necrosis factor-alpha inhibitor infliximab (Remicade). Br J Dermatol 2004;150:379–380.
15.
Mozzanica N, Cattaneo A: The clinical effect of topical calcipotriol in acrodermatitis continua of Hallopeau. Br J Dermatol 1998;138:556.
16.
Piraccini BM, Tosti A, Iorizzo M, Misciali C: Pustular psoriasis of the nails: Treatment and long-term follow-up of 46 patients. Br J Dermatol 2001;144:1000–1005.
17.
Skov L, Hansen ER, Baadsgaard O: Modulation of immunocytes by vitamin D; in Kragballe K (ed): Vitamin D in Dermatology. New York, Dekker, 2000, pp 133–141.
18.
Thiers BH: The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis. J Am Acad Dermatol 1997;37:S69–71.
19.
Schuster C, Zepter K, Kempf W, Dummer R: Successful treatment of recalcitrant chronic actinic dermatitis with tacrolimus. Dermatology 2004;209:325–328.
20.
Böhm M, Gaubitz M, Luger TA, Metze D, Bonsmann G: Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. Dermatology 2003;207:381–385.
21.
Nagao K, Ishiko A, Yokoyama T, Tanikawa A, Amagai M: A case of generalized pustular psoriasis treated with topical tacrolimus. Arch Dermatol 2003;139:1219.
22.
Assmann T, Ruzicka T: Other potential dermatological indications for tacrolimus; in Ruzicka T, Reitamo S (eds): Tacrolimus Ointment: A Topical Immunomodulator for Atopic Dermatitis. Berlin, Springer, 2004, pp 213–233.
23.
Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, Autio P, Lauerma AI: Tacrolimus does not affect collagen synthesis: Results of a single-center randomized trial. J Invest Dermatol 1998;111:396–398.
24.
Nghiem P, Pearson G, Langley RG: Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002;46:228–241.
25.
Garcia-Doval I, Cruces M: Topical tacrolimus in cutaneous lesions of dermatomyositis: Lack of effect in side-by-side comparison in five patients. Dermatology 2004;209:247–248.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.